Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.67 |
| ▸ | CA12 | O43570 | 2/20 | 0.67 |
| ▸ | CA4 | P22748 | 2/20 | 0.67 |
| ▸ | CA6 | P23280 | 2/20 | 0.67 |
| ▸ | CA7 | P43166 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 2/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.67 |
| ▸ | TPMT | P51580 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | TTR | P02766 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948203 | 1.00 | CA1 (0.67) | CA1CA2CA12CA4CA6 | |
| SCHEMBL458266 | 0.85 | CA1 (0.67) | CA1CA2CA12CA4CA6 | |
| SCHEMBL1808835 | 0.84 | MAPT (0.60) | CA1CA2CA12CA4CA6 | |
| SCHEMBL30740888 | 0.84 | MAPT (0.60) | CA1CA2CA12CA4CA6 | |
| SCHEMBL12775737 | 0.84 | MAPK1 (0.57) | CA1CA2CA12CA4CA6 | |
| SCHEMBL29953034 | 0.81 | TSHR (0.64) | CA1CA2CA12CA4CA6 | |
| SCHEMBL132609 | 0.81 | ERN1 (0.48) | CA1CA2CA12CA4CA6 | |
| SCHEMBL15148296 | 0.81 | PLK1 (0.51) | CA1CA2CA12CA4CA6 | |
| Veratric Acid SCHEMBL976032 | 0.80 | CA12 (1.00) | CA1CA2CA12CA4CA6 | |
| Veratric Acid SCHEMBL29386353 | 0.80 | CA12 (1.00) | CA1CA2CA12CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230076792-A1 | SEQUENTIAL TARGETING IN CROSSLINKING NANO-THERANOSTICS FOR TREATING BRAIN TUMORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-09 | — | — | US | claimed |
| CN-115551917-A | Sequential targeting of cross-linked nanotherapeutics for the treatment of brain tumors | 加利福尼亚大学董事会 | 2022-12-30 | — | — | CN | claimed |
| EP-4077477-A1 | SEQUENTIAL TARGETING IN CROSSLINKING NANO-THERANOSTICS FOR TREATING BRAIN TUMORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-10-26 | — | — | EP | claimed |
| WO-2021126970-A1 | SEQUENTIAL TARGETING IN CROSSLINKING NANO-THERANOSTICS FOR TREATING BRAIN TUMORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-24 | — | — | WO | claimed |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2026-05-26 | — | — | US | disclosed |
| CN-115551917-B | Sequential targeting of cross-linked nanotherapeutics for the treatment of brain tumors | 加利福尼亚大学董事会 | 2025-06-13 | — | — | CN | disclosed |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-06-05 | — | — | US | disclosed |
| EP-4452918-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-10-30 | — | — | EP | disclosed |
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-06-18 | — | — | US | disclosed |
| WO-2023122276-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-06-29 | — | — | WO | disclosed |
| CN-116003409-A | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20230113588-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-13 | — | — | US | disclosed |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
| WO-2009064414-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090023729-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1979331-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1979341-A1 | TRISUBSTITUTED AMINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007088999-A1 | TRISUBSTITUTED AMINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR3, FGFR2, FGFR1 | CA1 4659/4885CA2 3684/4885CA12 4396/4885 |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | CA1 1732/4885CA2 990/4885CA12 2731/4885 |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CA1 4156/4885CA2 4160/4885CA12 1432/4885 |
| US-20230113588-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | CA1 2985/4885CA2 1637/4885CA12 3836/4885 |
| US-20230076792-A1 | SEQUENTIAL TARGETING IN CROSSLINKING NANO-THERANOSTICS FOR TREATING BRAIN TUMORS | TIE1, CA12, CA13 | CA1 14/4885CA2 515/4885CA12 2/4885 |
| US-20090029994-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | CA1 4882/4885CA2 4793/4885CA12 4872/4885 |
| US-20090023729-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | CA1 4869/4885CA2 4794/4885CA12 4857/4885 |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | CA1 2469/4885CA2 666/4885CA12 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.